Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
2. Lu 2030
3. Lu-2-030
4. Thip
1. Thip
2. 64603-91-4
3. Gaboxadolum
4. Gaboxadolum [latin]
5. 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
6. Mk-0928
7. Lu 02-030
8. 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one
9. 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol
10. Lu-02-030
11. Prestwick-13b03
12. Lu-02030
13. Chebi:34373
14. 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2h)-one
15. K1m5rvl18s
16. Zinc19795995
17. Nsc-759585
18. Ncgc00015982-05
19. Isoxazolo(5,4-c)pyridin-3(2h)-one, 4,5,6,7-tetrahydro-
20. Isoxazolo[5,4-c]pyridin-3(2h)-one, 4,5,6,7-tetrahydro-
21. Gaboxadol [usan:inn]
22. Dsstox_cid_25206
23. Dsstox_rid_80750
24. Dsstox_gsid_45206
25. Gaboxadol [inn]
26. Cas-64603-91-4
27. Gaboxadol (usan/inn)
28. Einecs 264-963-0
29. Unii-k1m5rvl18s
30. 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3(2h)-one
31. Ei7
32. 4,5,6,7-tetrahydroisoxazole(5,4-c)pyridin-3-ol
33. Spectrum_001484
34. Tocris-0807
35. Gaboxadol [mi]
36. Lopac-t-101
37. Gaboxadol [usan]
38. Prestwick0_000972
39. Prestwick1_000972
40. Prestwick2_000972
41. Prestwick3_000972
42. Spectrum2_001590
43. Spectrum3_000728
44. Spectrum4_000172
45. Spectrum5_001907
46. Biomol-nt_000235
47. Gaboxadol [who-dd]
48. Lopac0_001233
49. Bspbio_001003
50. Bspbio_002256
51. Kbiogr_000683
52. Kbioss_001964
53. Divk1c_000211
54. Spbio_001560
55. Spbio_002914
56. Bpbio1_000420
57. Bpbio1_001105
58. Chembl312443
59. Gtpl4322
60. Dtxsid0045206
61. Bdbm82002
62. Kbio1_000211
63. Kbio2_001964
64. Kbio2_004532
65. Kbio2_007100
66. Kbio3_001476
67. Ninds_000211
68. Bcp07031
69. Nsc_3448
70. Tox21_110271
71. Bdbm50224809
72. Mfcd05664626
73. Ov-101
74. Akos006282519
75. Tox21_110271_1
76. Ccg-205307
77. Db06554
78. Nsc 759585
79. Sb18782
80. Sdccgsbi-0051200.p004
81. Idi1_000211
82. Ncgc00015982-01
83. Ncgc00015982-02
84. Ncgc00015982-03
85. Ncgc00015982-04
86. Ncgc00015982-06
87. Ncgc00015982-07
88. Ncgc00015982-13
89. Ncgc00024801-01
90. Ncgc00024801-02
91. Ncgc00024801-03
92. Ncgc00263653-01
93. Hy-10232
94. Sy253214
95. Sbi-0051200.p003
96. Cas_64603-91-4
97. Ab00053777
98. Cs-0002507
99. Ft-0774669
100. D04282
101. Ab00053777_07
102. 4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridin-3-ol
103. 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-one
104. 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-3-ol
105. 4h,5h,6h,7h-[1,2]oxazolo[5,4-c]pyridin-3-ol
106. Q4130924
107. 2h,3h,4h,5h,6h,7h-[1,2]oxazolo[5,4-c]pyridin-3-one
Molecular Weight | 140.14 g/mol |
---|---|
Molecular Formula | C6H8N2O2 |
XLogP3 | -0.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 0 |
Exact Mass | 140.058577502 g/mol |
Monoisotopic Mass | 140.058577502 g/mol |
Topological Polar Surface Area | 50.4 Ų |
Heavy Atom Count | 10 |
Formal Charge | 0 |
Complexity | 210 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in sleep disorders and insomnia.
GABA Agonists
Endogenous compounds and drugs that bind to and activate GAMMA-AMINOBUTYRIC ACID receptors (RECEPTORS, GABA). (See all compounds classified as GABA Agonists.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
ABOUT THIS PAGE
A Gaboxadol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gaboxadol, including repackagers and relabelers. The FDA regulates Gaboxadol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gaboxadol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gaboxadol supplier is an individual or a company that provides Gaboxadol active pharmaceutical ingredient (API) or Gaboxadol finished formulations upon request. The Gaboxadol suppliers may include Gaboxadol API manufacturers, exporters, distributors and traders.
Gaboxadol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gaboxadol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gaboxadol GMP manufacturer or Gaboxadol GMP API supplier for your needs.
A Gaboxadol CoA (Certificate of Analysis) is a formal document that attests to Gaboxadol's compliance with Gaboxadol specifications and serves as a tool for batch-level quality control.
Gaboxadol CoA mostly includes findings from lab analyses of a specific batch. For each Gaboxadol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gaboxadol may be tested according to a variety of international standards, such as European Pharmacopoeia (Gaboxadol EP), Gaboxadol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gaboxadol USP).
LOOKING FOR A SUPPLIER?